18β-Glycyrrhetinic acid (Synonyms: 18β甘草次酸)

目录号: HY-N0180 纯度: 99.88%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

18β-Glycyrrhetinic acid 是甘草的主要生物活性成分，具有抗溃疡，抗炎和抗增殖的特性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

18β-Glycyrrhetinic acid Chemical Structure

CAS No. : 471-53-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
5 g	￥850	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of 18β-Glycyrrhetinic acid:

18β-Glycyrrhetinic acid-d₃ In-stock
18α-Glycyrrhetinic acid In-stock
18β-Glycyrrhetinic acid (Standard) In-stock

MCE 顾客使用本产品发表的 13 篇科研文献

•SSRN. 2025 Jul 8.

18β-Glycyrrhetinic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
1A9	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 17591444]
4T1	IC₅₀	174.5 μM Compound: 1; GA	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
518A2	EC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
518A2	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	IC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 20932766]
518A2	IC₅₀	83.92 μM Compound: GA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
8505C	EC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
8505C	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 28033541]
8505C	IC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 20932766]
8505C	IC₅₀	86.5 μM Compound: GA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A-375	IC₅₀	98.14 μM Compound: 1; GA	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A-431	IC₅₀	79.58 μM Compound: GA	Cytotoxicity against human A431 cells after 96 hrs by SRB assay Cytotoxicity against human A431 cells after 96 hrs by SRB assay	[PMID: 20932766]
A2780	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A2780	IC₅₀	74.57 μM Compound: GA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 20932766]
A2780	IC₅₀	74.57 μM Compound: GA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A549	EC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
A549	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	GI₅₀	61.2 μM Compound: 1, GA	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 23122524]
A549	GI₅₀	> 100 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human A549 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human A549 after 3 days by MTT assay	[PMID: 21888390]
A549	IC₅₀	36.15 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30528976]
A549	IC₅₀	78 μg/mL Compound: GA	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by XTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by XTT assay	[PMID: 24461294]
A549	IC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 20932766]
A549	IC₅₀	82.76 μM Compound: GA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
A549	IC₅₀	84.25 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29486954]
A549	IC₅₀	94.97 μM Compound: 1; GA	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
A549	IC₅₀	> 30 μM Compound: GA	Inhibition of TNF-alpha induced NF-kappaB activation in human A549 cells after 7 hrs by Bright-Glo luciferase reporter gene assay Inhibition of TNF-alpha induced NF-kappaB activation in human A549 cells after 7 hrs by Bright-Glo luciferase reporter gene assay	[PMID: 30528976]
A549	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
A549/TR	IC₅₀	99.85 μM Compound: 3; GA	Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
B16-F10	GI₅₀	37 μM Compound: 1, GA	Growth inhibition in mouse B16F10 after 3 days by MTT assay Growth inhibition in mouse B16F10 after 3 days by MTT assay	[PMID: 21888390]
B16-F10	IC₅₀	138.8 μM Compound: 1; GA	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
Bel-7402	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
Bel-7402	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20932754]
Bel7402/5-FU	IC₅₀	69.77 μM Compound: 3; GA	Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
DLD-1	IC₅₀	81.21 μM Compound: GA	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 20932766]
DLD-1	IC₅₀	81.21 μM Compound: GA	Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
DU-145	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17591444]
DU-145	GI₅₀	64.9 μM Compound: 1, GA	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 23122524]
ECV-304	IC₅₀	101 μM Compound: Glycyrrhetinic acid	Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 22503361]
ECV-304	IC₅₀	292 μM Compound: Glycyrrhetinic acid	Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry	[PMID: 22503361]
Epidermoid carcinoma cell line	IC₅₀	>= 0.3 μM Compound: 18betaH-GA	Cytotoxicity against human Epidermoid carcinoma cell line Cytotoxicity against human Epidermoid carcinoma cell line	[PMID: 33383441]
FaDu	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
FaDu	IC₅₀	84.55 μM Compound: GA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 20932766]
FaDu	IC₅₀	84.55 μM Compound: GA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HCT-116	IC₅₀	78.83 μM Compound: GA	Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay	[PMID: 20932766]
HCT-116	IC₅₀	78.83 μM Compound: GA	Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HCT-116	IC₅₀	91.25 μM Compound: GA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29486954]
HCT-8	ED₅₀	19.5 μM Compound: 1, GA	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17591444]
HCT-8	IC₅₀	78.85 μM Compound: GA	Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay	[PMID: 20932766]
HCT-8	IC₅₀	78.85 μM Compound: GA	Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HEK293	IC₅₀	0.005 μM Compound: enoxolone	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	0.0086 μM Compound: Glycyrrhetinic acid	Inhibition of human 11beta HSD1 expressed in HEK293 cells assessed as assessed as inhibition of [1,2-(n)3H]cortisone to [3H]-cortisol after 60 mins by scintillation proximity assay Inhibition of human 11beta HSD1 expressed in HEK293 cells assessed as assessed as inhibition of [1,2-(n)3H]cortisone to [3H]-cortisol after 60 mins by scintillation proximity assay	[PMID: 21873057]
HEK293	IC₅₀	0.013 μM Compound: enoxolone	Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	1.2 nM Compound: GA	Inhibition of human 11beta-HSD2 overexpressed in microsomal fraction of HEK293 cells using [3H]-cortisol as substrate by scintillation proximity assay in presence of NAD+ Inhibition of human 11beta-HSD2 overexpressed in microsomal fraction of HEK293 cells using [3H]-cortisol as substrate by scintillation proximity assay in presence of NAD+	[PMID: 25590374]
HEK293	IC₅₀	1.3 nM Compound: 1; GA	Inhibition of full-length human 11beta-HSD2 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay Inhibition of full-length human 11beta-HSD2 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay	[PMID: 28458137]
HEK293	IC₅₀	11.3 nM Compound: 1; GA	Inhibition of full-length human 11beta-HSD1 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay Inhibition of full-length human 11beta-HSD1 expressed in HEK293 microsomal fraction using [3H]cortisone as substrate after 2 hr by scintillation proximity assay	[PMID: 28458137]
HEK293	IC₅₀	2 nM Compound: GA	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HEK293	IC₅₀	257 nM Compound: 1, GA	Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-[3H]cortisol to cortisone after 10 mins by scintillation counting Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-[3H]cortisol to cortisone after 10 mins by scintillation counting	[PMID: 21376605]
HEK293	IC₅₀	257 nM Compound: GA	Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-3H]-cortisol to cortisone by scintillation counting Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-3H]-cortisol to cortisone by scintillation counting	[PMID: 20851614]
HEK293	IC₅₀	29.1 nM Compound: GA	Inhibition of human 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HEK293	IC₅₀	29.1 nM Compound: GA	Inhibition of human 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH Inhibition of human 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH	[PMID: 25590374]
HEK293	IC₅₀	40.2 nM Compound: GA	Inhibition of mouse 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH Inhibition of mouse 11beta-HSD1 overexpressed in microsomal fraction of HEK293 cells assessed as formation of [3H]-cortisol from [3H]-cortisone by scintillation proximity assay in presence of NADPH	[PMID: 25590374]
HEK293	IC₅₀	778 nM Compound: 1, GA	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-[3H]cortisone to cortisol after 10 mins by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-[3H]cortisone to cortisol after 10 mins by scintillation counting	[PMID: 21376605]
HEK293	IC₅₀	778 nM Compound: GA	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]-cortisone to cortisol by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]-cortisone to cortisol by scintillation counting	[PMID: 20851614]
HEK293	IC₅₀	8.8 nM Compound: Glycyrrhetinic acid	Inhibition of human microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH Inhibition of human microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH	[PMID: 26936592]
HEK293	IC₅₀	9.4 nM Compound: Glycyrrhetinic acid	Inhibition of mouse microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH Inhibition of mouse microsomal 11beta-HSD1 overexpressed in HEK293 cells using [3H]-cortisone as substrate assessed as formation of [3H]-cortisol using [3H]cortisone by scintillation proximity assay in presence of NADPH	[PMID: 26936592]
HL-60	IC₅₀	55.28 μM Compound: GA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay	[PMID: 31883490]
HL-60	IC₅₀	63.2 μM Compound: 2; Glycyrrhetic acid	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	10.1039/C4MD00344F
HT-29	EC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
HT-29	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HT-29	IC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 20932766]
HT-29	IC₅₀	80.09 μM Compound: GA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
HeLa	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
HepG2	IC₅₀	44.51 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30528976]
HepG2	IC₅₀	81.42 μM Compound: GA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
HepG2	IC₅₀	94.45 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29486954]
HepG2	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
HepG2	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
HepG2	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20932754]
HepG2 2.2.15	CC₅₀	55.15 μM Compound: GA	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 22520261]
HepG2 2.2.15	CC₅₀	650 μM Compound: B1; GA	Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29627260]
HepG2 2.2.15	IC₅₀	130.49 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	20.86 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	39.28 μM Compound: GA	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication	[PMID: 22520261]
Hs 683	GI₅₀	84 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human Hs683 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human Hs683 after 3 days by MTT assay	[PMID: 21888390]
K562	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
K562/Adr	IC₅₀	86.46 μM Compound: 3; GA	Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
KB	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 17591444]
KB	GI₅₀	61.2 μM Compound: 1, GA	Growth inhibition of human KB cells by SRB assay Growth inhibition of human KB cells by SRB assay	[PMID: 23122524]
L02	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
L02	IC₅₀	> 200 μM Compound: GA	Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
L02	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 30528976]
LNCaP	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human LN-Cap cells Cytotoxicity against human LN-Cap cells	[PMID: 17591444]
MCF7	EC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
MCF7	EC₅₀	> 30 μM Compound: 3	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	> 30 μM Compound: GA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MCF7	GI₅₀	76 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human MCF7 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human MCF7 after 3 days by MTT assay	[PMID: 21888390]
MCF7	IC₅₀	32.6 μM Compound: 18betaH-GA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by ATP based luminometry Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by ATP based luminometry	[PMID: 33383441]
MCF7	IC₅₀	74.75 μM Compound: GA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29486954]
MCF7	IC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 20932766]
MCF7	IC₅₀	84.7 μM Compound: GA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
MCF7	IC₅₀	> 100 μM Compound: GA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	> 200 μM Compound: 3; GA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
MCF7	IC₅₀	> 40 μM Compound: GA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
MDA-MB-231	IC₅₀	146.6 μM Compound: 1; GA	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDCK	CC₅₀	7.4 μg/mL Compound: Glycyrrhetinic acid	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 36455358]
MDCK	IC₅₀	> 40 μM Compound: GA	Cytotoxicity against MDCK cells incubated for 72 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 72 hrs by MTT assay	[PMID: 31226654]
MG-63	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay	[PMID: 30528976]
MGC-803	IC₅₀	> 200 μM Compound: GA	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
MGC-803	IC₅₀	> 50 μM Compound: GA	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30528976]
MIA PaCa-2	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
NCI-H460	IC₅₀	37.65 μM Compound: GA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	62 μg/mL Compound: GA	Cytotoxicity against human NCI-H460 cells assessed as cell viability after 24 hrs by XTT assay Cytotoxicity against human NCI-H460 cells assessed as cell viability after 24 hrs by XTT assay	[PMID: 24461294]
NCI/ADR-RES	IC₅₀	74.49 μM Compound: 3; GA	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
NIH3T3	EC₅₀	18.7 μM Compound: 3	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	18.7 μM Compound: GA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
NIH3T3	IC₅₀	18.52 μM Compound: GA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 20932766]
NTUB1	IC₅₀	27.31 μM Compound: 1, 18beta-GA, GA	Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay	[PMID: 21696969]
PANC-1	IC₅₀	132.2 μM Compound: 1; GA	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PC-12	EC₅₀	0.89 μM Compound: 2	Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells	[PMID: 31924497]
PC-3	ED₅₀	> 21 μM Compound: 1, GA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17591444]
PC-3	GI₅₀	80 μM Compound: 1, GA	Growth inhibition in apoptosis-sensitive human PC3 after 3 days by MTT assay Growth inhibition in apoptosis-sensitive human PC3 after 3 days by MTT assay	[PMID: 21888390]
PC-3	GI₅₀	95.72 μM Compound: GA	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
PC-3	IC₅₀	105.24 μM Compound: GA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 31883490]
PC-3	IC₅₀	> 20 μM Compound: 2; Glycyrrhetic acid	Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
RAW264.7	IC₅₀	1.3 μM Compound: 3	Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay	[PMID: 19278854]
RAW264.7	IC₅₀	187.88 μM Compound: GA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method	[PMID: 23373965]
Raji	IC₅₀	> 80 μM Compound: Glycyrrhetic acid	Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue assay Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue assay	[PMID: 12608850]
SK-MEL-28	GI₅₀	92 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human SK-MEL-28 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human SK-MEL-28 after 3 days by MTT assay	[PMID: 21888390]
SK-OV-3	IC₅₀	45.62 μM Compound: GA	Growth inhibition of cisplatin sensitive human SKOV3 cells after 48 hrs by MTT assay Growth inhibition of cisplatin sensitive human SKOV3 cells after 48 hrs by MTT assay	[PMID: 30528976]
SW-1736	IC₅₀	76.93 μM Compound: GA	Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay	[PMID: 20932766]
SW-1736	IC₅₀	76.93 μM Compound: GA	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
SW480	IC₅₀	86.8 μM Compound: GA	Cytotoxicity against human SW480 cells after 96 hrs by SRB assay Cytotoxicity against human SW480 cells after 96 hrs by SRB assay	[PMID: 20932766]
SW480	IC₅₀	86.8 μM Compound: GA	Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay	[PMID: 20884085]
Sf21	IC₅₀	> 40 μM Compound: 7	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
T-24	IC₅₀	56.78 μM Compound: GA	Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
T98G	GI₅₀	85 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human T98G after 3 days by MTT assay Growth inhibition in apoptosis-resistant human T98G after 3 days by MTT assay	[PMID: 21888390]
U-373MG ATCC	GI₅₀	83 μM Compound: 1, GA	Growth inhibition in apoptosis-resistant human U373 after 3 days by MTT assay Growth inhibition in apoptosis-resistant human U373 after 3 days by MTT assay	[PMID: 21888390]

体外研究
(In Vitro)

18β-Glycyrrhetinic acid 是 Glycyrrhizae Radix 的主要生物活性成分，具有抗溃疡、抗炎和抗增殖作用。MTS 测定表明，18β-Glycyrrhetinic acid 处理 24 小时以剂量依赖性方式抑制两种细胞系中的细胞增殖。160 μM 的 18β-Glycyrrhetinic acid 显著降低活细胞百分比至 A549 中的约 40.5±10.5% 和 NCI-H460 中的 38.3±4.6% (分别为 p < 0.01)。当细胞用 320 μM 18β-Glycyrrhetinic acid 处理时，显示出对细胞增殖的更大抑制作用，因为与未处理的对照相比，活细胞的百分比低于 30% (p<0.001)。用 160 μM 和 320 μM 的 18β-Glycyrrhetinic acid 处理可降低全长 PARP 的水平并增加裂解 PARP 的水平^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

18β-Glycyrrhetinic acid +雷公藤内酯 (TP) 组给予低剂量 18β-Glycyrrhetinic acid (50 mg/kg) 的大鼠与TP大鼠相比，血清三项参数均有显著降低。18β-Glycyrrhetinic acid +TP组大鼠接受大剂量 18β-Glycyrrhetinic acid (100mg/kg) 后，三种肝酶水平略有下降，与TP组相比，下降幅度无统计学意义。相比之下，预先给予低剂量 18β-Glycyrrhetinic acid 可保护动物免受 TP 诱导的肝损伤。相反，低剂量 18β-Glycyrrhetinic acid (50 mg/kg) 显著抑制上述四种细胞因子的释放^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

470.68

Formula

C₃₀H₄₆O₄

CAS 号

471-53-4

性状

固体

颜色

White to off-white

中文名称

18β-甘草次酸

结构分类

初始来源

内源性代谢物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 125 mg/mL (265.57 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1246 mL	10.6229 mL	21.2459 mL
5 mM	0.4249 mL	2.1246 mL	4.2492 mL
10 mM	0.2125 mL	1.0623 mL	2.1246 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (4.61 mM); 澄清溶液

此方案可获得 ≥ 2.17 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.17 mg/mL (4.61 mM); 澄清溶液

此方案可获得 ≥ 2.17 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 25 mg/mL (53.11 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.88%

选择批次：

Data Sheet (652 KB) SDS (393 KB)

COA (294 KB) LCMS (274 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690. [Content Brief]

[2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. [Content Brief]

[3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320. [Content Brief]

Cell Assay ^[2]	Primary microglia cultures are used in this study. For treatment assay, microglia are incubated with complete DMEM and stimulated with or without 100 ng/mL IFN-γ in the presence or absence of 18β-Glycyrrhetinic acid (25 μM and 50 μM) at 37°C in a humidified incubator with 5% CO₂. For cell migration assay, the isolated primary microglia that seeded in complete DMEM medium are stimulated with or without IFN-γ (100 ng/mL), and treated with different doses of 18β-Glycyrrhetinic acid, 24 h later, the microglia culture supernatants are collected and added to the lower chambers of Transwell inserts^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Healthy Wistar rats (male, 200±20 g) are used and divided into five groups with 10 individuals for each group randomly. Animals in normal control (NC) group receive distilled water for 6 days and 0.5% CMC-Na for the last 3 days. Rats in Triptolide model group (TP), 18β-Glycyrrhetinic acid low-dose group (GAL+TP), and 18β-Glycyrrhetinic acid high-dose group (GAH+TP) receive distilled water, 18β-Glycyrrhetinic acid (50 mg/kg, p.o., dissolved in distilled water), or 18β-Glycyrrhetinic acid (100 mg/kg, p.o., dissolved in distilled water) for consecutive 6 days, respectively, and liver injury is induced by TP (2.4 mg/kg, p.o., suspended in 0.5% CMC-Na) for the last 3 days. Animals in the above three groups receive TP 6 hours after distilled water or 18β-Glycyrrhetinic acid treatment on the last 3 days^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690. [Content Brief] [2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. [Content Brief] [3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320. [Content Brief]

18β-Glycyrrhetinic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1246 mL	10.6229 mL	21.2459 mL	53.1146 mL
	5 mM	0.4249 mL	2.1246 mL	4.2492 mL	10.6229 mL
	10 mM	0.2125 mL	1.0623 mL	2.1246 mL	5.3115 mL
	15 mM	0.1416 mL	0.7082 mL	1.4164 mL	3.5410 mL
	20 mM	0.1062 mL	0.5311 mL	1.0623 mL	2.6557 mL
	25 mM	0.0850 mL	0.4249 mL	0.8498 mL	2.1246 mL
	30 mM	0.0708 mL	0.3541 mL	0.7082 mL	1.7705 mL
	40 mM	0.0531 mL	0.2656 mL	0.5311 mL	1.3279 mL
	50 mM	0.0425 mL	0.2125 mL	0.4249 mL	1.0623 mL
	60 mM	0.0354 mL	0.1770 mL	0.3541 mL	0.8852 mL
	80 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6639 mL
	100 mM	0.0212 mL	0.1062 mL	0.2125 mL	0.5311 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

18β-Glycyrrhetinic acid471-53-418β-甘草次酸Endogenous MetaboliteInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

18β-Glycyrrhetinic acid (Synonyms: 18β甘草次酸)

Customer Review

Other Forms of 18β-Glycyrrhetinic acid:

MCE 顾客使用本产品发表的 13 篇科研文献

18β-Glycyrrhetinic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

18β-Glycyrrhetinic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

18β-Glycyrrhetinic acid (Synonyms: 18β甘草次酸)

Customer Review

Other Forms of 18β-Glycyrrhetinic acid:

18β-Glycyrrhetinic acid 相关抗体

MCE 顾客使用本产品发表的 13 篇科研文献

18β-Glycyrrhetinic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

18β-Glycyrrhetinic acid 相关抗体:

摩尔计算器

稀释计算器

18β-Glycyrrhetinic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z